717907-75-0 | N-[3-[[[2-[(2,3-Dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methyl-methanesulfonamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$108.00	$76.00
5mg	98%	in stock	$262.00	$183.00
10mg	98%	in stock	$369.00	$259.00
50mg	98%	in stock	$1,674.00	$1,172.00
100mg	98%	in stock	$2,856.00	$1,999.00

Description

• Catalog Number: AH13178
• Chemical Name: N-[3-[[[2-[(2,3-Dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methyl-methanesulfonamide
• CAS Number: 717907-75-0
• Molecular Formula: C21H20F3N7O3S
• Molecular Weight: 507.4888
• MDL Number: MFCD16038299
• SMILES: O=C1Nc2c(C1)cc(cc2)Nc1ncc(c(n1)NCc1cccnc1N(S(=O)(=O)C)C)C(F)(F)F

Computed Properties

• Complexity: 856
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 12
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 2

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.

  International journal of cancer 20120715

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation.

  Arthritis and rheumatism 20120501

• Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.

  Molecular cancer therapeutics 20111101

• Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.

  Anti-cancer agents in medicinal chemistry 20110901

• Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.

  Oncogene 20101209

• Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.

  Cancer biology & therapy 20100701

• Emerging targets in osteoporosis disease modification.

  Journal of medicinal chemistry 20100610

• Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.

  Cancer biology & therapy 20090501

• Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.

  Breast cancer research : BCR 20090101

• Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases.

  Cancer 20080515

• Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

  Cancer research 20080315